Alcon Company Profile

02:41 EST 20th November 2017 | BioPortfolio

The Alcon group's U.S. headquarters in Fort Worth, Texas, (about 30 miles west of Dallas) is our largest location with over 2,500 employees. We continue to build our team for the future across the United States and worldwide.
We seek dedicated individuals who share our vision of diversified specialization in the field of ophthalmology -- people who are committed to their careers as a means of securing a successful future for themselves while adding value to the world in which they live.


6201 S. Freeway
Fort Worth
United States of America


Phone: 41+41-785-8888

News Articles [60 Associated News Articles listed on BioPortfolio]

Novartis steigert Gewinn und hält vorerst an Alcon fest

FRANKFURT (Dow Jones)--Der schweizerische Pharmakonzern Novartis hat im dritten Quartal 2017 mehr verdient und ist bei der strategischen Überprüfung seiner Augensparte Alcon vorangekommen. Die Sch.....

Novartis CEO reasserts 2018 growth expectations, discusses Alcon and Sandoz future

Novartis has reiterated its expectation of sales growth beginning in 2018, as well as a positive outlook for its Alcon eye care business, according to Chief Executive Joe Jimenez (pictured). Jimenez t...

Novartis-Aktie: Konzern bestätigt Prognose - Alcon läuft etwas besser

Dem Schweizer Pharmakonzern Novartis hat auch im zweiten Quartal die Sanierung des Augenheilgeschäfts Alcon und Generika-Konkurrenz für sein wichtiges Blutkrebsmittel Glivec zu schaffen gemacht. De....

Novartis hält Umsatz in Q3 stabil - Entscheid zu Alcon verschoben - Aktie im Minus

So hat der Konzern im dritten Quartal bei Umsatz und Gewinn leicht über den Erwartungen abgeschnitten. Gespannter haben die Investoren aber noch auf die Aussagen zur Zukunft der Augensparte Alcon g.....

Novartis-VRP: Update zu Alcon im Oktober - Innovation wird noch wichtiger

Zürich (awp) - Der Pharmakonzern Novartis will gemäss früheren Informationen zusammen mit den Q3-Zahlen (24.10.) ein Update zu den Plänen mit der Augenheilsparte Alcon geben. "Dabei bleibt es", sa...

Novartis mit mehr Licht als Schatten in Q3 - Alcon-Entscheidung vertagt

(Zusammenfassung) Basel (awp) - Wenn Novartis etwas im dritten Quartal gezeigt hat, dann, dass es auch anders kann als negativ überraschen. Während über viele Quartals die Augensparte Alcon und auc...

Novartis Q3: Cosentyx growing fast, no decision yet on Alcon

Novartis saw its sales rise 2% in the third quarter, thanks to steady overall growth in its innovative medicines division, and a strong 7% increase from its Alcon eye division. The company is flying ...

Novartis verschiebt Entscheid über Zukunft von Alcon

Zürich (awp) - Für den Entscheid über die weitere Zukunft der Augenheilsparte Alcon braucht Novartis noch mehr Zeit. Eine mögliche Transaktion sei nicht vor dem ersten Halbjahr 2019 wahrscheinlich...

Drugs and Medications [97 Associated Drugs and Medications listed on BioPortfolio]

Bion tears [Alcon Laboratories, Inc.]


Systane [Alcon Laboratories, Inc.]

SYSTANE® BALANCE Lubricant Eye Drops

Systane [Alcon Research Ltd]

SystaneLubricant Eye Drops

Systane [Alcon Research Ltd]

Systane ULTRALubricant Eye Drops

Naphcon a®eye drops [ALCON LABORATORIES, INC.]

Naphcon A®Eye Drops

PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

Evaluation of Postoperative Astigmatism Correction and Postoperative Rotational Stability of Two Toric Intraocular Lenses.

Background The aim of this retrospective study was to evaluate the rotational stability and the refractive outcome of two different toric IOLs. Methods This study included 41 eyes with corneal astigma...

Prospective Evaluation of Outcomes in Patients Undergoing Treatment for Myopia Using the WaveLight Refractive Suite.

To evaluate outcomes in patients with myopia up to -12.00 diopters (D), with or without astigmatism up to 6.00 D, who underwent LASIK with the WaveLight Refractive Suite (Alcon Laboratories, Inc., For...

Impact of Near Addition on the Optical Quality of Diffractive Multifocal Intraocular Lenses - a Laboratory Study Using an Optical Bench.

Purpose To analyse the optical quality of diffractive multifocal intraocular lenses (IOLs) with different near additions in a laboratory study. Methods We analysed the AcrySof(®) IQ ReSTOR(®) + 2....

Single-Spot Yellow Laser Versus Conventional Green Laser on Panretinal Photocoagulation: Patient Pain Scores and Preferences.

Panretinal photocoagulation (PRP) is the mainstay therapy for proliferative diabetic retinopathy. Pain during and after its application is a complication that affects patients' therapeutic adherence. ...

Retrospective Analysis of the Post-Operative Changes in Higher-Order Aberrations: A Comparison of the WaveLight EX500 to the VISX S4 Laser in Refractive Surgery.

In an attempt to maximize treatment outcomes, refractive surgery techniques are being directed toward customized ablations to correct not only lower-order aberrations but also higher-order aberrations...

Clinical Trials [25 Associated Clinical Trials listed on BioPortfolio]

Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof

This study is to compare intraindividually the functional vision provided by two different posterior chamber intraocular lenses: AMO Tecnis Z9000 and Alcon SA60AT Acrysoft. To see if the a...

Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens

The purpose of this study is to determine if reduced lens deposits and increased comfort can be achieved by using Multipurpose disinfecting solutions (MPDS) in a no-rub format but in conju...

Prospective Comparative Study of Refractive Outcome of STAAR and Alcon Toric Intraocular Lenses

Several methods have been developed to address and reduce preexisting astigmatism. The refractive results associated with the use of toric IOLs are likely to be more predictable. Other adv...

Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery

This randomized controlled trial compares two regimens of topical therapy: - tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day - combination of tobr...

LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser vs AMO Visx Wavefront-Guided Excimer Laser

The purpose of the study is to compare the results of LASIK surgery when using Alcon Allegretto wavefront-guided excimer laser system compared to AMO Visx Custom wavefront-guided excimer l...

Companies [9 Associated Companies listed on BioPortfolio]

Alcon, Inc.

Alcon, Inc. is the world’s leading eye care company, with sales of approximately $6.5 billion in 2009. Alcon, which has been dedicated to the ophthalmic industry for 65 years...


The Alcon group's U.S. headquarters in Fort Worth, Texas, (about 30 miles west of Dallas) is our largest location with over 2,500 employees. We continue to build our team for the future across the Uni...

StrikeForce Communications LLC

StrikeForce is an award-winning full service agency with a stack of consumer and professional accounts. Clients include both industry giants and specialty companies such as Abbott...

LaVoie Group

LaVoie Group provides senior-level strategic counsel and tactical implementation of strategic communications programs designed to properly position, create visibility and drive value for each client. ...

PanOptica, Inc.

PanOptica, Inc. is a private, venture-backed biopharmaceutical company focused on licensing and developing a portfolio of exciting and innovative therapeutics for major ophthalmic diseases. Since its ...

More Information about "Alcon" on BioPortfolio

We have published hundreds of Alcon news stories on BioPortfolio along with dozens of Alcon Clinical Trials and PubMed Articles about Alcon for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alcon Companies in our database. You can also find out about relevant Alcon Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record